Our vision is to become the leading innovator of gene-based therapies
FIT Biotech is a biotechnology company headquartered in Tampere, Finland. The company aims to become a leader in the development of gene-based treatments. Our most advanced product is a DNA vaccine FIT-06 that we develop for treating HIV.
The FIT-06 vaccine is currently being developed in an extensive European research project (EHVA). This co-operation project consists of 39 operators and has received significant financing from EU Horizon 2020 programme as well as from Switzerland. FIT Biotech produces preparations (FIT-06 vaccines) for the research team.
Our unique patented gene transfer technology allows the development of numerous drug candidates for a range of different pharmaceutical applications. Our technological platforms (GTU, gtGTU) can be used in treatments for a range of different conditions, including cancer and a number of different infectious diseases, such as HIV. The clinical tests of FIT-06 vaccines have shown that the DNA based technology of FIT Biotech is safe, fast and cost-efficient.
The end goal of FIT Biotech is to position applications of its technology as an alternative to biologics, such as vaccines, antibodies and protein-based drugs.
Our gene transfer technology offers a technological advantage in the form of scalability, providing a platform to develop gene-based therapies at a faster rate and at lower production costs. This means better and safer therapies for patients.
Our team has a collective total of almost 100 years of experience in the pharmaceutical industry, with almost 20 years of cGMP (current Good Manufacturing Practices) level manufacturing, which is unique for a company such as ours. We are working under the supervision of the Finnish Medicines Agency Fimea. Fimea certifications cover all of the devices, equipment, staff and operating practices. In our production facilities we can produce DNA-based vaccines used in preclinical research and clinical trials.
We have multiple on-going drug development projects and collaborative projects with international biotech companies and academic research institutions. We also have a broad research collaboration network, which strengthens our position as a frontrunner in the biotech sector and as a distinguished drug development company.
FIT Biotech Oy was founded in 1995. Our shares are being traded on Nasdaq's First North Helsinki marketplace. FIT Biotech currently employs 13 biotech experts. Our objective is to create revenue by developing GTU© gtGTU© based drug candidates for preclinical or early stage clinical trials. After this, the drug candidates are licensed to bigger pharmaceutical companies and biotech companies for further development. In addition, we have an extensive international co-operation network in business and academic world.